Synthetic lethality-based drugs and targets market is estimated to be worth USD 8 billion in 2030, “predicts Roots Analysis”
Advances in molecular screening technology have enabled the
identification of novel synthetic lethal gene combinations, enabling the
development of lead candidates that leverage the aforementioned phenomenon to
offer therapeutic benefit.
Roots
Analysis is pleased to
announce the publication of its recent study, titled, “Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on
DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways”.
The report features an extensive study of the
current market landscape, offering an informed opinion on the likely adoption
of such compact diagnostic devices, over the next decade. The report features
an in-depth analysis, highlighting the capabilities of various stakeholders
engaged in this domain. In addition to other elements, the study includes:
§ A
detailed assessment of the current market landscape, providing information on
drug developer(s) phase of development, type of molecule, type of therapy, type
of synlet target, target patient segment, key therapeutic area(s), target
indication(s), and route of administration. In addition, the chapter includes a
list of screening platforms that are being used by industry players to study
synlet interactions between gene pairs.
§ Detailed
profiles of players that are engaged in the development of synthetic
lethality-based drugs, featuring a brief overview of the company, its financial
information (if available), detailed profiles of their respective lead drug
candidates, and an informed future outlook.
§ An
analysis of the prevalent and emerging trends in this domain, as represented on
the social media platform, Twitter, posted during the period 2010-2019 (till
May), highlighting the historical trend of tweets, most prolific contributors,
frequently discussed synlet targets, popular disease indications and a
multivariate tweet benchmark analysis.
§ An
analysis of close to 700 peer-reviewed scientific articles related to synthetic
lethality, published during the period 2017-2019 (till May), highlighting the
research focus within this niche industry segment.
§ An
analysis of various abstracts presented at the American Society of Clinical
Oncology (ASCO) in the time period 2013-2019 (till May), highlighting several
parameters, such as year of (abstract) publication, popular drugs, synlet
targets, target cancer indications, popular authors, author designations,
industry type (industry and academia) and most active organizations (in terms
of number of published abstracts).
§ An
in-depth analysis of close to 750 grants that have been awarded to research
institutes engaged in projects related to synthetic lethality, between 2014 and
2019 (till May), highlighting various important parameters associated with
grants, such as year of award, support period, amount awarded, funding
institute, administration institute center, funding institute center, funding
mechanism, spending categorization, grant type, responsible study section,
focus area, type of recipient organization and prominent program officers.
§ An
analysis of the investments made into companies that have proprietary synthetic
lethality-based drugs / screening platforms, including seed financing, venture
capital financing, debt financing, grants, capital raised from IPOs and
subsequent offerings.
§ An
in-depth benchmark analysis of over 230 synlet targets identified from various
credible sources (research publications, government fundings, clinical studies,
recent news / tweets and abstracts presented in global conferences),
highlighting targets that have already been validated in clinical studies,
preclinical studies and early-stage research (cases where there is no lead
(therapeutic) candidate being investigated). Further, it highlights the
long-term opportunities (for drug developers) associated with individual
targets, based on their popularity across different portals.
§ An
analysis of the role of innovative companion diagnostics in synthetic lethality
on the basis of several parameters, such as synlet target, drug candidate(s)
being investigated, target biomarker(s), target disease indication(s) and assay
technique used. It also includes case studies, highlighting those companion
diagnostic tests that are available and are being used to evaluate the
therapeutic efficiency of approved PARP inhibitors using the principle of
synthetic lethality.
§ A detailed market forecast, featuring analysis
of the current and projected future opportunity across key market segments
(listed below)
§ Type
of Molecule
§
Small Molecule
§
Biologic
§ Target
Indication
§
Breast Cancer
§
Cervical / Anogenital Cancer
§
Diabetic Macular Edema
§
Gastric Cancer
§
Lung Cancer
§
Ovarian Cancer
§
Renal Cell Cancer
§ Synlet
Target
§ APE
/ REF-1
§ CHK1
§ GLS1
§ PARP
§ Polθ
§ WEE1
§ Route
of Administration
§
Oral
§
Intravenous
§ Key
Geographical Regions
§ North
America
§ Europe
§ Asia-Pacific
§ Rest
of the World
§ Transcripts of interviews held with the
following senior level representatives of stakeholder companies
§
Simon Boulton (Vice President, Science Strategy, Artios Pharma)
§
Yi Xu (Associate Director, Business Development, IMPACT Therapeutics)
§
Norbert Perrimon (Professor, Department of Genetics, Harvard Medical School)
§
Vivek Dharwal (Professor, Department of Biochemistry, Panjab University)
§
Alfred Nijkerk (Chief Executive Officer, UbiQ)
Key
companies covered in the report
§ AbbVie
§ AstraZeneca
§ AtlasMedx
§ BeiGene
§ Chordia
Therapeutics
§ Clovis
Oncology
§ GlaxoSmithKline
§ IDEAYA
Biosciences
§ Mission
Therapeutics
§ Pfizer
§ Repare
Therapeutics
§ Sierra
Oncology
§ SyntheX
Labs
For
more information please click on the following link:
Other Recent Offerings
1.
Global
T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030
2.
Neoantigen
Targeted Therapies Market, 2019-2030
3.
Cancer
Biomarkers Market: Focus On TMB, MSI / MMR and TILS Testing, 2019 – 2030
4.
Companion
Diagnostics Market (2nd Edition), 2019-2030
About Roots Analysis
Roots Analysis is one of the fastest growing market
research companies, sharing fresh and independent perspectives in the
bio-pharmaceutical industry. The in-depth research, analysis and insights are
driven by an experienced leadership team which has gained many years of
significant experience in this sector. If you’d like help with your growing
business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
Comments
Post a Comment